Last updated: February 17, 2026
What Is the Market Status for NDC 43598-0265?
The drug with NDC 43598-0265 is marketed as Xyrem (sodium oxynitrate). Manufactured by Jazz Pharmaceuticals, Xyrem is primarily used to treat narcolepsy with cataplexy and idiopathic hypersomnia. Its market environment is shaped by regulatory rulings, competitive landscape, and patent protections.
How Large Is the Xyrem Market?
Xyrem’s global sales peaked at approximately $943 million in 2021, driven by its FDA-approved indications and high prescribing rates within sleep disorder treatments. The drug benefits from a strong patent portfolio that expires in early 2027, instituting a timeline for market exclusivity. Its primary markets include the United States, European Union, and select Asian economies.
Key Market Dynamics:
- Regulatory exclusivity: 17-year patent protection, expiring in 2027.
- Pricing: U.S. average wholesale price (AWP) is roughly $28,000 per 30-day supply (per literature, 2022). Discounts and reimbursement policies reduce net price.
- Referral and prescribing trends: Steady growth correlates with narcolepsy diagnosis rates (~200,000 patients in the U.S.), with continued physician adoption.
What Are Current Price Levels and Price Trends?
Pricing:
- In the U.S., the wholesale acquisition cost (WAC) for each 30-day supply of Xyrem is approximately $28,000.
- Discounting models, including rebates and insurance negotiations, lower the net price to insurers and providers by roughly 15–25%.
Trend insights:
- Since 2018, prices have increased by an average of 3–4% annually.
- No significant generic competition exists until at least 2027, which may impact prices.
- Price increases have been stable but face potential regulation pressures in the U.S. due to rising drug affordability concerns.
Market Competition and Patent Outlook
Patent Landscape:
- The core composition patent expires in 2027.
- Secondary patents related to formulations and manufacturing methods extend protection until 2029–2030.
- After patent expiration, generic versions are expected to enter the market, likely reducing prices by 50% or more.
Competitor Landscape:
- Currently no approved generics in the U.S.
- Key competitors in the narcolepsy space include off-label treatments like stimulants, and off-label use of other medications.
- The novel drug market is limited, but biosimilar development could influence the landscape post-2027.
Price Projections Through the Patent Lifecycle
| Year |
Estimated Price (per 30-day supply) |
Notes |
| 2023 |
$28,000 |
Stable; patent protections remain |
| 2024 |
$28,900 |
Slight increase, inflation-adjusted |
| 2025 |
$29,800 |
Continued modest growth |
| 2026 |
$30,700 |
Pre-patent expiry; stable |
| 2027 |
$15,000–$20,000 |
Post-patent expiration; generic entries expected |
| 2028+ |
$10,000 or lower |
Price reductions post-generic competition |
Source for projections: assumptions based on historical trends, patent expiry schedules, and market behavior.
Risks to Price Stability and Market Share
- Patent expiration: The 2027 expiry radically alters pricing and market share.
- Regulatory interventions: Price caps and biosimilar policies could suppress prices pre- and post-patent.
- Market shifts: Increased off-label and alternative therapies could impact demand.
Key Takeaways:
- The current global market for NDC 43598-0265 exceeds $900 million.
- U.S. prices average approximately $28,000 per 30-day supply and are expected to grow modestly until patent expiry.
- Patent protections last until 2027, after which generic competition will likely halve prices.
- Market growth depends on narcolepsy prevalence, prescriber adoption, and regulatory factors.
- Post-2027 pricing could be significantly lower due to generic competition, with prices possibly dropping below $10,000 per 30 days.
FAQs
1. When will generic versions of Xyrem become available?
Generic versions are likely around 2027, following patent expiry.
2. How will patent expiry affect Xyrem’s pricing?
Prices could decrease by at least 50%, with further reductions due to generic competition and payer negotiations.
3. Are there ongoing regulatory risks impacting Xyrem’s market?
Yes. Price regulation initiatives in the U.S. and potential biosimilar policies can influence future pricing and market dynamics.
4. How does Xyrem compare price-wise to similar treatments?
Xyrem’s current wholesale price is higher than alternative narcolepsy treatments, which often range from $10,000 to $20,000 annually.
5. What strategies could Jazz Pharmaceuticals pursue beyond patent expiry?
Diversification into new indications, formulation improvements, or development of biosimilars could sustain revenue streams.
Citations
[1] IQVIA, "Global Biotechnology & Pharma Market Data," 2022.
[2] U.S. Food and Drug Administration, "Xyrem (sodium oxybate) Approval," 2002.
[3] Jazz Pharmaceuticals, Annual Reports, 2018–2022.
